Novartis AG’s multiple sclerosis pill Gilenya will cost 1,850 euros ($2,645) for 28 days in Germany, according to a company spokesman.
Novartis AG has stopped deliveries to a second German wholesaler over a disagreement on prices for its medicines.
The prices of multiple sclerosis medicines have risen as much as 39 percent since last year, even as competition intensified with the introduction of the first pill to treat the disease.
Novartis AG said a multiple sclerosis patient died on Nov. 23 after starting treatment with Gilenya, the first pill approved to treat the debilitating neurological disease.
Novartis AG’s sales representatives are covered by federal wage-and-hour laws requiring payment of overtime, a U.S. appeals court in New York ruled.
Novartis AG said a former employee who alleges the Swiss drugmaker asked her to give doctors kickbacks for sales has made a 5 million-yuan ($817,000) compensation claim against the company.
Sanofi, Novartis AG, Merck & Co. and Roche Holding AG worked with the same travel agency under investigation by Chinese authorities as part of a probe of GlaxoSmithKline Plc over allegations of bribery and corruption.
Novartis AG has identified its animal-health business as a top candidate for a sale as Chairman Joerg Reinhardt revamps the Swiss drugmaker, according to three people familiar with the matter.
"Novartis strongly rejects the Italian law allowing reimbursement of Avastin to be used off-label in the eye for economic reason as it is against European law."
- Eric Althoff on Jun 10, 2014